Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the <i>In Vitro</i> Potency of Cabotegravir or Rilpivirine-Reference-Cited by-同舟云学术

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine

Published:2022-03-15 Issue:3 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jeffrey Jerry L.¹^ORCID,St. Clair Marty¹,Wang Ping¹,Wang Chunfu²,Li Zhufang²,Beloor Jagadish²,Talarico Christine¹,Fridell Robert²,Krystal Mark²^ORCID,White C. Thomas¹,Griffith Sandy¹,D’Amico Ronald¹,Smith Kimberly¹,Van Eygen Veerle³,Vingerhoets Johan³,Vandermeulen Kati³,Spreen William¹,van Lunzen Jan⁴

Affiliation:

1. ViiV Healthcare, Research Triangle Park, North Carolina, USA

2. ViiV Healthcare, Branford, Connecticut, USA

3. Janssen Pharmaceutica NV, Beerse, Belgium

4. ViiV Healthcare, Brentford, United Kingdom

Abstract

The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression. Three participants who received long-acting therapy had confirmed virologic failure (CVF) at Week 48, and all had HIV-1 that was originally classified as subtype A1 and contained the baseline integrase polymorphism L74I; updated classification algorithms reclassified all 3 as HIV-1 subtype A6.

Funder

ViiV Healthcare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01702-21

Reference49 articles.

1. Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis

2. The Survival Benefits of AIDS Treatment in the United States

3. Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

4. World Health Organization. 2019. Update of recommendations on first- and second-line antiretroviral regimens (WHO/CDS/HIV/19.15). World Health Organization, Geneva, Switzerland.

5. European AIDS Clinical Society. 2020. Guidelines: version 10.1. European AIDS Clinical Society, Brussels, Belgium.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors’ Phenotypic Susceptibility;AIDS Research and Human Retroviruses;2024-08-20

2. Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine;Journal of Antimicrobial Chemotherapy;2024-06-21

3. An update on long-acting agents in HIV therapy;Future Virology;2023-09

4. Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6;The Journal of Infectious Diseases;2023-07-27

5. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure;Clinical Infectious Diseases;2023-06-21